156469-00-0 Usage
Description
(2R)-3-cyclohexyl-2-hydroxypropionic acid, also known as chiral cyclohexylglycolic acid, is a chiral chemical compound with the molecular formula C8H14O3. It possesses two enantiomers, which are mirror images of each other. (2R)-3-cyclohexyl-2-hydroxypropionic acid is widely used in organic synthesis, particularly for the production of pharmaceuticals and other fine chemicals. It has also been studied for its potential applications in asymmetric catalysis and for its therapeutic properties, such as in the treatment of neurological disorders and as an anti-inflammatory agent.
Uses
Used in Pharmaceutical Industry:
(2R)-3-cyclohexyl-2-hydroxypropionic acid is used as a key intermediate in the synthesis of various pharmaceuticals and fine chemicals. Its chiral nature allows for the production of enantiomerically pure compounds, which are essential for the development of effective and safe medications.
Used in Asymmetric Catalysis:
(2R)-3-cyclohexyl-2-hydroxypropionic acid is utilized as a chiral ligand or catalyst in asymmetric catalysis, enabling the selective formation of enantiomerically pure products. This is crucial for the synthesis of biologically active compounds and the development of enantioselective processes in the chemical industry.
Used in Neurological Disorders Treatment:
(2R)-3-cyclohexyl-2-hydroxypropionic acid has been investigated for its potential therapeutic properties in the treatment of neurological disorders. Its ability to modulate specific biological pathways and target receptors makes it a promising candidate for the development of novel treatments for various neurological conditions.
Used as an Anti-Inflammatory Agent:
(2R)-3-cyclohexyl-2-hydroxypropionic acid has also been studied for its potential as an anti-inflammatory agent. Its ability to reduce inflammation and modulate immune responses may contribute to the development of new therapies for inflammatory diseases and conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 156469-00-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,6,4,6 and 9 respectively; the second part has 2 digits, 0 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 156469-00:
(8*1)+(7*5)+(6*6)+(5*4)+(4*6)+(3*9)+(2*0)+(1*0)=150
150 % 10 = 0
So 156469-00-0 is a valid CAS Registry Number.
156469-00-0Relevant articles and documents
HETEROARYLS AMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATORS
-
Page/Page column 52-53, (2010/04/06)
The present invention provides Formula (1A) compounds that act as glucokinase activators; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by glucokinase. X, Y, Z, R1, R2, R3, and R4 are as described herein.
Biocatalytic racemisation of α-hydroxycarboxylic acids at physiological conditions
Glueck, Silvia M.,Larissegger-Schnell, Barbara,Csar, Katrin,Kroutil, Wolfgang,Faber, Kurt
, p. 1904 - 1905 (2007/10/03)
Biocatalytic racemisation of aliphatic, aryl-aliphatic and aromatic α-hydroxycarboxylic acids was accomplished using whole resting cells of Lactobacillus paracasei DSM 20207; the mild (physiological) reaction conditions ensured an essentially 'clean' isomerization in the absence of side reactions, such as elimination or decomposition. The Royal Society of Chemistry 2005.
Process research of (R)-cyclohexyl lactic acid and related building blocks: A comparative study
Storz, Thomas,Dittmar, Peter,Fauquex, Pierre Francois,Marschal, Philippe,Lottenbach, Willy Urs,Steiner, Heinz
, p. 559 - 570 (2013/09/05)
(S)-Cyclohexyl lactic acid is a component of the selective E-selectin inhibitor 2 ((S)-cHexLact-2-0-(3-Galβ(1→3)ddGlc-(4→1)αFuc). We describe the evaluation of various synthetic routes to this building block: (A) diazotation of phenylalanine followed by phenyl ring hydrogenation; (B) phenyl ring hydrogenation of phenyl alanine followed by diazotation; (C) acidic hydrolysis of the cyanohydrin derived from phenylacetaldehyde, enantiomeric resolution of the resulting, racemic phenyl lactic acid via diasteromeric salt formation and phenyl ring hydrogenation; (D) enantioselective dihydroxylation of a cinnamate ester, followed by hydrogenation of the benzylic hydroxy group and the aromatic nucleus; (E) enantioselective biocatalytic reduction of phenylpyruvic acid, followed by phenyl ring hydrogenation. The development of (2R)-2-0-(4-nitrophenyl)sulfonyl-cyclohexyl lactic acid p-bromobenzylester 21 as a buidling block with improved crystallinity and stability is also described.
